Revvity's 2025 Guidance Signals Cautious Optimism Amid Slower-Than-Expected Pharma Spending Recovery

After significant business transformation activities in recent years, Revvity (formerly PerkinElmer) has been in a constant state of evolution since 2016 when the company made the transition into two new business segments, diagnostics, and discovery and analytical solutions, or DAS. With the recent divestment of its Applied, Food, and Enterprise Services business in early 2023, the company is operating under a new name and will focus solely on the life sciences and diagnostics business. We believe the firm's renewed strategic focus on improving its diagnostic product mix and life sciences business will maintain returns over cost of capital and produce tangible benefits for shareholders in the long run.